$NXTC News

Last published 1d ago

1d agoNXTCNextCure, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1d agoNXTCNextCure Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireBALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.
3mo agoNXTCAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001PR NewswireAvere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory...
3mo agoNXTCNextCure Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireAnnounced Proposed Merger with Avere TherapeuticsPreserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) --
4mo agoNXTC AKRONextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 TherapyGlobeNewswireAvere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient,
5mo agoNXTCNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic CancersGlobeNewswireBELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the
5mo agoNXTCNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026GlobeNewswire55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability in heavily pretreated
6mo agoNXTCNextCure Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireSIM0505/CDH6 ADC dose optimization initiated in gynecologic cancersSIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026
6mo agoNXTCNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic CancersGlobeNewswireDose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md., May 04, 2026 (GLOBE
6mo agoNXTCNextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026GlobeNewswireBELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to
7mo agoNXTCNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian CancerGlobeNewswireThe U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026;
7mo agoNXTCNextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026GlobeNewswireBELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to
8mo agoNXTCNextCure Provides Business Update and Reports Full Year 2025 Financial ResultsGlobeNewswireData readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned in second half of
9mo agoNXTCNextCure Provides Business UpdateGlobeNewswireSIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure,
11mo agoNXTCNextCure to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireBELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
11mo agoNXTCNextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data ReadoutsGlobeNewswireExtends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept ("POC") data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management,
12mo agoNXTCNextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq RulesGlobeNewswireBELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced that it has entered
1y agoNXTCNextCure Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireBELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to
1y agoNXTCNextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United StatesGlobeNewswireFirst U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025
1y agoNXTCNextCure to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireBELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
1y agoNXTCNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswireAnnounced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of
1y agoNXTCPreclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis ImperfectaGlobeNewswireBELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
1y agoNXTCNextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6GlobeNewswireNextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third
1y agoNXTCNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025GlobeNewswireLNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose
1y agoNXTCNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsGlobeNewswireDosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash
1y agoNXTCNextCure to Present at 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireBELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
1y agoNXTCNextCure Provides Business Update and Reports Full Year 2024 Financial ResultsGlobeNewswireCompleted cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund
1y agoNXTCNextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersGlobeNewswireBELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to
1y agoNXTCNextCure Announces Acceptance of IND Application for LNCB74GlobeNewswireBELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to
1y agoNXTCNextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewswireBELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
1y agoNXTCPreclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaGlobeNewswireBELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
2y agoNXTCNextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswirePrioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024
2y agoNXTCNextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingGlobeNewswirePreclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-endAdditional biomarker data support
2y agoNXTCNextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingGlobeNewswireBELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
2y agoNXTCNextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024GlobeNewswireOf the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism of action of NC410
2y agoNXTCNextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsGlobeNewswireLNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected to fund operations
2y agoNXTCNextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceGlobeNewswireBELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies,
2y agoNXTCNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024GlobeNewswireOf the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease
2y agoNXTCNextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewswirePhase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to
2y agoNXTCNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024GlobeNewswireBELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
2y agoNXTCNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024GlobeNewswireBELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
2y agoNXTCNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardGlobeNewswireBELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
2y agoNXTCNextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireBELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
2y agoNXTCNextCure Provides Business Update and Reports Full Year 2023 Financial ResultsGlobeNewswirePrioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts with data updates in
2y agoNXTCNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesGlobeNewswireBELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
2y agoNXTCNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersGlobeNewswireBELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
2y agoNXTCNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryGlobeNewswireBELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
2y agoNXTCNextCure Provides Year-End Clinical Pipeline UpdatesGlobeNewswireBELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
2y agoNXTCNextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceGlobeNewswireBELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
2y agoNXTCNextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLGlobeNewswireNew publication in Journal of Clinical Investigation provides compelling evidence for NC525's ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modelingUpdate for ongoing Phase 1a